Not all patients with CLL have to have therapy. Despite all new advancements, the iwCLL nevertheless recommends watchful observation for sufferers with asymptomatic disease.86 This suggestion is predicated on at the least two randomized trials evaluating observation to either chlorambucil monotherapy or fludarabine, cyclophosphamide and rituximab (